We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
Read MoreHide Full Article
IGM Biosciences, Inc.’s (IGMS - Free Report) share price nearly doubled on Tuesday, after the company announced that it has entered into an exclusive partnership with Sanofi (SNY - Free Report) to create, develop and commercialize new therapies targeting oncology, immunology, and inflammation indications.
The collaboration will utilize IGM Biosciences’ proprietary IgM antibody technology platform to discover IgM antibody agonists, which will target six indications — three in oncology and another three in immunology/inflammation.
Per the agreement terms, Sanofi will pay an upfront payment of $150 million to IGMS. In addition, SNY may pick up a non-voting stake in the company up to $100 million in public financing. IGMS will be eligible to receive more than $6 billion in milestone payments.
In the year so far, ImmunoGen’s stock price has declined 0.6% in comparison with the industry’s 11.2% decline.
For each oncology target picked as part of the deal, IGM Biosciences will lead all research and development activities till its regulatory approval. In return, IGMS will be eligible to receive an aggregate sum of $940 million per onology target in potential milestone payments. All subsequent development and commercialization activities post regulatory approval will be headed by Sanofi. While both the companies will share profits equally in certain major markets, IGMS will receive tiered royalties on net sales in the remaining markets.
For each immunology/inflammation target picked per the deal, IGM Biosciences will lead all research and development activities till the completion of the phase I study for up to two constructs directed to each immunology/inflammation target. In return, IGMS will be eligible to receive an aggregate sum of $1,065 million per target. All subsequent development and commercialization activities post the phase I study will be led by SNY. IGMS will be eligible to receive tiered royalties on global net sales.
This deal is likely to yield benefits for IGM Biosciences, which does not have any marketed product in its portfolio and lacks a stable stream of revenues. In fact, the company’s most advance candidate is IGM-2323, which recently entered into two phase II studies for treating patients with diffuse large B cell lymphoma and follicular lymphoma.
IGM Biosciences currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the overall healthcare sector are Collegium Pharmaceutical (COLL - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) . While Collegium Pharmaceutical sports a Zacks Rank #1 (Strong Buy), Vertex Pharmaceuticals carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Collegium Pharmaceutical’s earnings per share estimates for 2022 have increased from $3.79 to $5.76 in the past 60 days. The same for 2023 has increased from $4.79 to $7.96 in the past 60 days. Shares of COLL have risen 8% year to date.
Earnings of Collegium Pharmaceutical beat estimates in three of the last four quarters and missed the mark on one occasion, with the negative surprise being 57.6%.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $14.33 to $14.52 in the past 60 days. Shares of VRTX have risen 17.5% year to date.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, with the average being 10%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
IGM Biosciences, Inc.’s (IGMS - Free Report) share price nearly doubled on Tuesday, after the company announced that it has entered into an exclusive partnership with Sanofi (SNY - Free Report) to create, develop and commercialize new therapies targeting oncology, immunology, and inflammation indications.
The collaboration will utilize IGM Biosciences’ proprietary IgM antibody technology platform to discover IgM antibody agonists, which will target six indications — three in oncology and another three in immunology/inflammation.
Per the agreement terms, Sanofi will pay an upfront payment of $150 million to IGMS. In addition, SNY may pick up a non-voting stake in the company up to $100 million in public financing. IGMS will be eligible to receive more than $6 billion in milestone payments.
In the year so far, ImmunoGen’s stock price has declined 0.6% in comparison with the industry’s 11.2% decline.
For each oncology target picked as part of the deal, IGM Biosciences will lead all research and development activities till its regulatory approval. In return, IGMS will be eligible to receive an aggregate sum of $940 million per onology target in potential milestone payments. All subsequent development and commercialization activities post regulatory approval will be headed by Sanofi. While both the companies will share profits equally in certain major markets, IGMS will receive tiered royalties on net sales in the remaining markets.
For each immunology/inflammation target picked per the deal, IGM Biosciences will lead all research and development activities till the completion of the phase I study for up to two constructs directed to each immunology/inflammation target. In return, IGMS will be eligible to receive an aggregate sum of $1,065 million per target. All subsequent development and commercialization activities post the phase I study will be led by SNY. IGMS will be eligible to receive tiered royalties on global net sales.
This deal is likely to yield benefits for IGM Biosciences, which does not have any marketed product in its portfolio and lacks a stable stream of revenues. In fact, the company’s most advance candidate is IGM-2323, which recently entered into two phase II studies for treating patients with diffuse large B cell lymphoma and follicular lymphoma.
IGM Biosciences, Inc. Price
IGM Biosciences, Inc. price | IGM Biosciences, Inc. Quote
Zacks Rank & Stocks to Consider
IGM Biosciences currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the overall healthcare sector are Collegium Pharmaceutical (COLL - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) . While Collegium Pharmaceutical sports a Zacks Rank #1 (Strong Buy), Vertex Pharmaceuticals carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Collegium Pharmaceutical’s earnings per share estimates for 2022 have increased from $3.79 to $5.76 in the past 60 days. The same for 2023 has increased from $4.79 to $7.96 in the past 60 days. Shares of COLL have risen 8% year to date.
Earnings of Collegium Pharmaceutical beat estimates in three of the last four quarters and missed the mark on one occasion, with the negative surprise being 57.6%.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $14.33 to $14.52 in the past 60 days. Shares of VRTX have risen 17.5% year to date.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, with the average being 10%.